Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir

被引:15
作者
Alessandri-Gradt, Elodie [1 ]
Charpentier, Charlotte [2 ]
Leoz, Marie [1 ]
Mourez, Thomas [1 ]
Descamps, Diane [2 ]
Plantier, Jean-Christophe [1 ]
机构
[1] Normandie Univ, CHU Rouen, Lab Virol Associe CNR VIH, UNIROUEN,GRAM,EA2656, F-76000 Rouen, France
[2] Univ Paris Diderot, Sorbonne Paris Cite, Hop Bichat, AP HP,Lab Virol,IAME,INSERM,UMR 1137, Paris, France
关键词
PHASE; 2B; BMS-626529; PRODRUG; RESISTANCE; SAFETY; BMS-663068; PREVALENCE; EFFICACY; AI438011;
D O I
10.1093/jac/dky271
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Fostemsavir belongs to the new class of attachment inhibitors (AIs); it inhibits the entry of HIV into CD4+ T-lymphocytes by blocking conformational changes in gp120. This is a promising AI, but previous phenotypic data showed that genetically divergent HIV-1 group O could present natural resistance to this drug. These data were obtained from only two strains, which are not representative of the high intra-group genetic diversity. Moreover, no data are available concerning the other divergent HIV-1 groups (N and P). Objectives: To further investigate the natural genotypic susceptibility of HIV-1 groups O, N and P (HIV-1 non-M) to fostemsavir, using a large set of sequences. Methods: The frequency of eight substitutions associated with decreased susceptibility to fostemsavir (L116P, A204D, S375M/H, M426L, M434I, M475I and V506M), was investigated in 111 gp120 sequences from groups O (n - 100), N (n - 9) and P (n - 2), Results: All HIV-1 group N sequences harboured the three substitut ons S375M, M426L and M434I, whereas only 1% and 10% of HIV-1 group O sequences harboured the S375H + M426L and S375H + M434I patterns, respectively. The main genetic profile of HIV-1 groups P and O combined S375H with two atypical substitutions (M426S and M434L). Five group O sequences did not display any of the eight substitutions, but had atypical residues with unknown impact. Conclusions: The genetic polymorphisms in the g p120 of HIV-1 non-M viruses support the hypothesis that these viruses could largely be resistant to inhibition by fostemsavir. Only 5% of group O strains could display full genetic susceptibility. Extensive phenotypic studies are now required.
引用
收藏
页码:2716 / 2720
页数:5
相关论文
共 19 条
  • [1] HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors
    Alessandri-Gradt, E.
    Collin, G.
    Tourneroche, A.
    Bertine, M.
    Leoz, M.
    Charpentier, C.
    Unal, G.
    Descamps, D.
    Plantier, J. C.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (09) : 2431 - 2437
  • [2] Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients
    Charpentier, Charlotte
    Larrouy, Lucile
    Visseaux, Benoit
    Landman, Roland
    Levittas, Marine
    Storto, Alexandre
    Damond, Florence
    Yazdanpanah, Yazdan
    Yeni, Patrick
    Brun-Vezinet, Francoise
    Descamps, Diane
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (06) : 1459 - 1461
  • [3] Depatureaux Agnes, 2011, J Acquir Immune Defic Syndr, V56, P139, DOI 10.1097/QAI.0b013e318201a904
  • [4] Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: In vitro phenotypic and genotypic analyses
    Descamps, D
    Collin, G
    Letourneur, F
    Apetrei, C
    Damond, F
    LoussertAjaka, I
    Simon, F
    Saragosti, S
    BrunVezinet, F
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (11) : 8893 - 8898
  • [5] Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes
    Fofana, Djeneba B.
    Charpentier, Charlotte
    Maiga, Almoustapha I.
    Lambert-Niclot, Sidonie
    Sayon, Sophie
    Desire, Nathalie
    Simon, Anne
    Yazdanpanah, Yazdan
    Katlama, Christine
    Descamps, Diane
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    Soulie, Cathia
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (01) : 130 - 135
  • [6] Kozal M, 2017, 16 EUR AIDS C MIL IT
  • [7] Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial
    Lalezari, Jacob P.
    Latiff, Gulam H.
    Brinson, Cynthia
    Echevarria, Juan
    Trevino-Perez, Sandra
    Bogner, Johannes R.
    Thompson, Melanie
    Fourie, Jan
    Sussmann Pena, Otto A.
    Mendo Urbina, Fernando C.
    Martins, Marcelo
    Diaconescu, Iulian G.
    Stock, David A.
    Joshi, Samit R.
    Hanna, George J.
    Lataillade, Max
    [J]. LANCET HIV, 2015, 2 (10): : E427 - E437
  • [8] Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action
    Langley, David R.
    Kimura, S. Roy
    Sivaprakasam, Prasanna
    Zhou, Nannan
    Dicker, Ira
    McAuliffe, Brian
    Wang, Tao
    Kadow, John F.
    Meanwell, Nicholas A.
    Krystal, Mark
    [J]. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2015, 83 (02) : 331 - 350
  • [9] Lataillade M, 2018, JAIDS-J ACQ IMM DEF, V77, P299, DOI [10.1097/qai.0000000000001602, 10.1097/QAI.0000000000001602]
  • [10] The Two-Phase Emergence of Non Pandemic HIV-1 Group O in Cameroon
    Leoz, Marie
    Feyertag, Felix
    Kfutwah, Anfumbom
    Mauclere, Philippe
    Lachenal, Guillaume
    Damond, Florence
    De Oliveira, Fabienne
    Lemee, Veronique
    Simon, Francois
    Robertson, David L.
    Plantier, Jean-Christophe
    [J]. PLOS PATHOGENS, 2015, 11 (08)